Bioventus
Stock Forecast, Prediction & Price Target
Bioventus Financial Estimates
Bioventus Revenue Estimates
Bioventus EBITDA Estimates
Bioventus Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $430.89M N/A | $512.11M 18.84% | $512.34M 0.04% | Avg: $574.53M Low: $571.96M High: $576.25M avg. 12.13% | Avg: $608.70M Low: $605.98M High: $610.52M avg. 5.94% | ||
Net Income
% change YoY
| $9.58M N/A | $-213.39M -2326.06% | $-156.23M 26.78% | Avg: $8.09M Low: $-11.27M High: $626.47K avg. 105.17% | Avg: $35.89M Low: $8.71M High: $8.80M avg. 343.69% | ||
EBITDA
% change YoY
| $52.59M N/A | $31.12M -40.81% | $-23.07M -174.11% | Avg: $78.09M Low: $77.74M High: $78.33M avg. 438.52% | Avg: $82.74M Low: $82.37M High: $82.98M avg. 5.94% | ||
EPS
% change YoY
| $0.16 N/A | -$3.48 -2275% | -$2.49 28.44% | Avg: -$0.09 Low: -$0.18 High: $0.01 avg. 96.58% | Avg: $0.14 Low: $0.14 High: $0.14 avg. 264.70% | ||
Operating Expenses
% change YoY
| $281.65M N/A | $379.7M 34.81% | $409.91M 7.95% | Avg: $343.57M Low: $342.04M High: $344.60M avg. -16.18% | Avg: $364.01M Low: $362.38M High: $365.09M avg. 5.94% | ||
FAQ
What is Bioventus stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 224.43% in 2025-2026.
We have gathered data from 2 analysts. Their low estimate is -11.27M, average is 8.09M and high is 626.47K.
What is Bioventus stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 9.04% in 2025-2026.
We have gathered data from 2 analysts. Their low revenue estimate is $571.96M, average is $574.53M and high is $576.25M.
What is Bioventus stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 180.64% in 2025-2026.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.18, average is -$0.09 and high is $0.01.
What is the best performing analyst?
In the last twelve months analysts have been covering Bioventus stock. The most successful analyst is William Plovanic.